Clinical efficacy of rituximab in the treatment of pemphigus vulgaris: A 10‐year follow‐up

Laftah, Zainab; Craythorne, Emma; Mufti, Ghulam J.; Vivier, Anthony du

doi:10.1111/jop.12948

Cited by 5 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical evaluation of RTX used during pemphigus vulgaris therapy revealed a remission in up to 73.3% of patients [2] and significant decrease in the risk of side effects during long-term glucocorticosteroid treatment [5]. There are also more arguments in the literature for the use of RTX as the first line of therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Dawka prednizonu wynosi 0,3 mg/kg, a dawka azatiopryny 100 mg/dobę z planem jej dalszego zmniejszenia. omóWienie W ocenie skuteczności klinicznej RTX w terapii pęcherzycy zwykłej wykazano remisję u nawet 73,3% chorych [2], a także znamienne zmniejszenie ryzyka wystąpienia działań niepożądanych występujących podczas długotrwałego leczenia glikokortykosteroidami [5]. W dostępnym piśmiennictwie są też inne argumenty przemawiające za stosowaniem RTX w leczeniu pierwszego wyboru.…”

Section: Discussionunclassified

See 1 more Smart Citation

Therapeutic difficulties related to optimization of pemphigus vulgaris treatment

Leonik¹,

Karpińska²,

Owsińska³

et al. 2020

View full text Add to dashboard Cite

A 60-year-old man with extensive erosive lesions within the scalp and face, limbs, trunk, and nasal and oral mucous membrane involvement was admitted to the ward with worsening of symptoms in the course of pemphigus vulgaris. The exacerbation took place during an attempt to reduce doses of immunosuppressive drugs and glucocorticosteroids. Additional examinations, otorhinolaryngological and dental consultation did not show another cause of this condition. Biological therapy with a monoclonal antibody directed against the CD20 antigen, rituximab, was introduced. The study presents the treatment efficacy in the patient 2 weeks after the last drug dose and compares them with the latest available knowledge on rituximab therapy in pemphigus vulgaris.streszczenie Sześćdziesięcioletni mężczyzna z rozległymi zmianami nadżerkowymi w obrębie owłosionej skóry głowy, a także na skórze twarzy, kończyn, tułowia, błony śluzowej nosa i jamy ustnej został przyjęty do Kliniki z powodu nasilenia objawów w przebiegu pęcherzycy zwykłej. Do zaostrzenia doszło podczas próby zmniejszenia przyjmowanych przez pacjenta dawek leków immunosupresyjnych i glikokortykosteroidów. Dodatkowe badania, konsultacja otorynolaryngologiczna i stomatologiczna nie wykazały innej przyczyny zaostrzenia. Chorego zakwalifikowano do terapii biologicznej z wykorzystaniem przeciwciała monoklonalnego skierowanego przeciwko antygenowi CD20. W pracy przedstawiono efekty leczenia pacjenta po 2 tygodniach od podania ostatniej dawki leku i zestawiono je z najnowszą dostępną wiedzą dotyczącą stosowania rytuksymabu w terapii pęcherzycy zwykłej.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionunclassified

Therapeutic difficulties related to optimization of pemphigus vulgaris treatment

Leonik¹,

Karpińska²,

Owsińska³

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Pemphigus vulgaris (PV) is a chronic autoimmune bullous disease induced by IgG autoantibodies against desmoglein 3, typically presenting with blisters, erosions, and ulcers of the skin and/or mucous membranes due to intraepidermal acantholysis. 1 Lesions of the oral cavity, characterized by pseudo‐membranes covering painful ulcers, frequently appear on the soft palate, buccae, lips, tongue, and/or gingiva. Conventional treatment of oral PV includes the combination of systemic corticosteroids and additional immunosuppressive drugs, whereby some patients undergo severe side effects, relapses or are found to be non‐responders.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pemphigus vulgaris with refractory gingival ulcerations, successfully treated with rituximab—A case report

Dolenc‐Voljč

Povšič

Kučič

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…RTX has been used as first‐line intervention together with short‐term prednisone in patients with mucosal‐cutaneous PV and it was suggested to be more effective than prednisone alone, with fewer adverse events . Few data are on RTX effectiveness are available for predominantly oral PV, and most of the studies report different regimens; moreover, it has been not yet used as a first‐line intervention in oral cases …”

Section: Introductionmentioning

confidence: 99%

The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation

Arduino

Broccoletti

Carbone

et al. 2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background The systemic use of corticosteroid is the treatment of choice for patients with pemphigus vulgaris (PV), but adverse effects are frequent. To date, the use of rituximab (RTX) for PV patients is usually indicated when they failed first‐line immunosuppressive therapies. The early use of RTX could theoretically lessen adverse effects. Methods We performed a single‐center study on patients with predominantly oral PV, treated with systemic corticosteroid and the prompt use of 1000 mg of intravenous RTX two weeks apart. We evaluated the clinical response and the reported adverse effect during a period of 24 months, comparing those with a previously published series. Results The study group comprised 11 patients, while the control group comprised 98 patients. The average time to achieve complete clinical remission was 3.2 ± 2.72 months. Study group took steroids for a mean time of 11.09 ± 2.02 months, and they are all actually disease‐free with no medication. Only three patients (27.3%) developed plain side effects. The effect of the length of the corticosteroid therapy on the side effects (also adjusted by sex, age, and clinical oral involvement) was statistically different in the two groups: the prompt use of RTX reduced of 94% the chance to have adverse effects (P = .001). Conclusions This is the first report of the use of RTX as first line of therapy for PV patients with predominantly oral involvement. With the proposed regimen, the adverse effects have been minimized compared with classic systemic corticosteroid‐centered therapy. Multi‐center randomized controlled trail is however necessary.

show abstract

Clinical efficacy of rituximab in the treatment of pemphigus vulgaris: A 10‐year follow‐up

Cited by 5 publications

References 5 publications

Therapeutic difficulties related to optimization of pemphigus vulgaris treatment

Therapeutic difficulties related to optimization of pemphigus vulgaris treatment

Pemphigus vulgaris with refractory gingival ulcerations, successfully treated with rituximab—A case report

The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation

Contact Info

Product

Resources

About